PMID- 35644972
OWN - NLM
STAT- MEDLINE
DCOM- 20220603
LR  - 20220606
IS  - 0253-9624 (Print)
IS  - 0253-9624 (Linking)
VI  - 56
IP  - 5
DP  - 2022 May 6
TI  - [Genetic variants, circulating levels of monocyte chemoattractant protein-1 with 
      risk of breast cancer: a case-control study and Mendelian randomization 
      analysis].
PG  - 590-594
LID - 10.3760/cma.j.cn112150-20211107-01030 [doi]
AB  - Objective: To assess the association of genetic polymorphisms and circulating 
      levels of chemokine monocyte chemoattractant protein-1 (MCP1) with risk of breast 
      cancer. Methods: A total of 820 patients with pathologically confirmed breast 
      cancer and 900 age-and area-of-residence-matched healthy controls who visited the 
      hospital for routine health screening during the same period were included in 
      this case-control study. Mendelian randomization analysis was performed using 
      three widely followed functional single nucleotide polymorphisms (SNPs) of the 
      MCP1 gene rs1024611, rs2857656 and rs4586 to construct instrumental variables. 
      Results: MCP1 rs1024611 (OR=1.26, P=0.002), rs2857656 (OR=1.23, P=0.006) and 
      rs4586 (OR=1.23, P=0.003) were significantly associated with increased risk of 
      breast cancer. SNP rs1024611 (beta=1.194, P<0.001), rs2857656 (beta=1.221, P<0.001) and 
      rs4586 (beta=1.137, P<0.001) were positively correlated with higher circulating 
      level of MCP1. The case-control study showed that an increase of 23.7 pg/ml of 
      circulating levels of MCP1 was associated with a 0.25-fold increased risk of 
      breast cancer. MR analysis confirmed that the genetic predicted circulating 
      levels of MCP1 were associated with an increased risk of breast cancer, and the 
      risk of breast cancer increased by 0.20 times with an increase of 23.7 pg/ml in 
      MCP1. Conclusion: Genetic variants and circulating levels of MCP1 are 
      significantly associated with the risk of breast cancer and can be used as a 
      biomarker for early prediction of breast cancer.
FAU - Miao, K K
AU  - Miao KK
AD  - Department of Breast Surgery, the First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou 450000, China.
FAU - Li, J
AU  - Li J
AD  - Department of Breast Surgery, the First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou 450000, China.
FAU - Wu, L N
AU  - Wu LN
AD  - Department of Breast Surgery, the First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou 450000, China.
FAU - Zhang, B
AU  - Zhang B
AD  - Department of Breast Surgery, the First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou 450000, China.
FAU - Li, M Q
AU  - Li MQ
AD  - Department of Breast Surgery, the First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou 450000, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Yu Fang Yi Xue Za Zhi
JT  - Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
JID - 7904962
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
SB  - IM
MH  - *Breast Neoplasms/genetics
MH  - Case-Control Studies
MH  - *Chemokine CCL2/genetics
MH  - Female
MH  - Humans
MH  - Mendelian Randomization Analysis
MH  - Polymorphism, Single Nucleotide
EDAT- 2022/06/02 06:00
MHDA- 2022/06/07 06:00
CRDT- 2022/06/01 11:02
PHST- 2022/06/01 11:02 [entrez]
PHST- 2022/06/02 06:00 [pubmed]
PHST- 2022/06/07 06:00 [medline]
AID - 10.3760/cma.j.cn112150-20211107-01030 [doi]
PST - ppublish
SO  - Zhonghua Yu Fang Yi Xue Za Zhi. 2022 May 6;56(5):590-594. doi: 
      10.3760/cma.j.cn112150-20211107-01030.